Latest Mental Health News

Emyria reports sustained six-month improvements in treatment-resistant PTSD patients and announces a strategic research collaboration with Australian National University to advance mental health care models.

Westpac Banking Corporation posted a $3.5 billion net profit for the first half of 2025, maintaining strong capital ratios and advancing its digital transformation and sustainability initiatives despite a slight earnings dip.

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Ramsay Health Care has announced a significant $305 million impairment in its UK segment driven by challenges at Elysium, alongside a $64.5 million tax provision release linked to Ramsay Santé. The company is taking decisive steps to address operational weaknesses while its core UK hospitals show promising growth.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

HeraMED reports a surge in its HeraCARE platform users and secures $4.1 million in new funding, underpinning its expansion in the US maternity care market and integration with major health systems.

Ramsay Health Care announces key leadership departures and a strategic realignment aimed at strengthening its core Australian hospital business and accelerating transformation under CEO Natalie Davis.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.